Reatividade cruzada de anticorpos desenvolvidos após a vacinação com tríplice viral (SCR) com as proteínas do SARS-CoV-2.

Abstract

INTRODUCTION: COVID-19 was the world's biggest health emergency from 2019 to today. The possible cross-reactivity of antibodies generated by the MMR vaccine and the antigens of SARS-CoV2 could be an alternative to containing the disease and treating it. Objective: Investigate the protection promoted by MMR antibodies against SARS-CoV2 infection and severe forms of COVID-19. METHODOLOGY: This is a cross-sectional study in which professionals in health care and the general population present positive and/or negative serology for SARS-CoV2 and who have or do not have a MMR vaccination. Sera of subjects were tested for SARS-CoV2 to detect IgM and/or IgG antibodies by immunochromatography, as well as a history of MMR vaccination. ELISAs were performed to detect antibodies against S1, S1RBD, S2, and N-protein and to mumps, measles, and rubella. RESULTS: Individuals vaccinated with MMR had protection against severe forms of COVID-19, presenting a lower production of IgG-class antibodies against S1RBD and N-protein compared to MMR-unvaccinated subjects. These individuals vaccinated with MMR were asymptomatic for SARS-CoV2 compared to unvaccinated subjects. CONCLUSION: MMR-vaccinated subjects have remarkable protection against SARS-CoV2 infection or, when infected, have milder symptoms compared to unvaccinated individuals.